174 related articles for article (PubMed ID: 26496174)
21. Conserved electrostatic fields at the Ras-effector interface measured through vibrational Stark effect spectroscopy explain the difference in tilt angle in the Ras binding domains of Raf and RalGDS.
Walker DM; Wang R; Webb LJ
Phys Chem Chem Phys; 2014 Oct; 16(37):20047-60. PubMed ID: 25127074
[TBL] [Abstract][Full Text] [Related]
22. PTEN expression controls cellular response to cetuximab by mediating PI3K/AKT and RAS/RAF/MAPK downstream signaling in KRAS wild-type, hormone refractory prostate cancer cells.
Bouali S; Chrétien AS; Ramacci C; Rouyer M; Becuwe P; Merlin JL
Oncol Rep; 2009 Mar; 21(3):731-5. PubMed ID: 19212633
[TBL] [Abstract][Full Text] [Related]
23. Elevated levels of ornithine decarboxylase cooperate with Raf/ERK activation to convert normal keratinocytes into invasive malignant cells.
Hayes CS; DeFeo K; Lan L; Paul B; Sell C; Gilmour SK
Oncogene; 2006 Mar; 25(10):1543-53. PubMed ID: 16278677
[TBL] [Abstract][Full Text] [Related]
24. RalGDS comes of age.
Rodriguez-Viciana P; McCormick F
Cancer Cell; 2005 Mar; 7(3):205-6. PubMed ID: 15766656
[TBL] [Abstract][Full Text] [Related]
25. p21ras initiates Rac-1 but not phosphatidyl inositol 3 kinase/PKB, mediated signaling pathways in T lymphocytes.
Genot E; Reif K; Beach S; Kramer I; Cantrell D
Oncogene; 1998 Oct; 17(13):1731-8. PubMed ID: 9796702
[TBL] [Abstract][Full Text] [Related]
26. GTP-Dependent K-Ras Dimerization.
Muratcioglu S; Chavan TS; Freed BC; Jang H; Khavrutskii L; Freed RN; Dyba MA; Stefanisko K; Tarasov SG; Gursoy A; Keskin O; Tarasova NI; Gaponenko V; Nussinov R
Structure; 2015 Jul; 23(7):1325-35. PubMed ID: 26051715
[TBL] [Abstract][Full Text] [Related]
27. Functional interactions of Raf and MEK with Jun-N-terminal kinase (JNK) result in a positive feedback loop on the oncogenic Ras signaling pathway.
Adler V; Qu Y; Smith SJ; Izotova L; Pestka S; Kung HF; Lin M; Friedman FK; Chie L; Chung D; Boutjdir M; Pincus MR
Biochemistry; 2005 Aug; 44(32):10784-95. PubMed ID: 16086581
[TBL] [Abstract][Full Text] [Related]
28. K-Ras G-domain binding with signaling lipid phosphatidylinositol (4,5)-phosphate (PIP2): membrane association, protein orientation, and function.
Cao S; Chung S; Kim S; Li Z; Manor D; Buck M
J Biol Chem; 2019 Apr; 294(17):7068-7084. PubMed ID: 30792310
[TBL] [Abstract][Full Text] [Related]
29. Intrinsic protein disorder in oncogenic KRAS signaling.
Nussinov R; Jang H; Tsai CJ; Liao TJ; Li S; Fushman D; Zhang J
Cell Mol Life Sci; 2017 Sep; 74(17):3245-3261. PubMed ID: 28597297
[TBL] [Abstract][Full Text] [Related]
30. Oncogenic KRas mobility in the membrane and signaling response.
Nussinov R; Tsai CJ; Jang H
Semin Cancer Biol; 2019 Feb; 54():109-113. PubMed ID: 29499269
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic Ras Isoforms Signaling Specificity at the Membrane.
Nussinov R; Tsai CJ; Jang H
Cancer Res; 2018 Feb; 78(3):593-602. PubMed ID: 29273632
[TBL] [Abstract][Full Text] [Related]
32. Constitutive activation of the Raf-MAPK pathway causes negative feedback inhibition of Ras-PI3K-AKT and cellular arrest through the EphA2 receptor.
Menges CW; McCance DJ
Oncogene; 2008 May; 27(20):2934-40. PubMed ID: 18059341
[TBL] [Abstract][Full Text] [Related]
33. RalGDS family members couple Ras to Ral signalling and that's not all.
Ferro E; Trabalzini L
Cell Signal; 2010 Dec; 22(12):1804-10. PubMed ID: 20478380
[TBL] [Abstract][Full Text] [Related]
34. K-Ras promotes growth transformation and invasion of immortalized human pancreatic cells by Raf and phosphatidylinositol 3-kinase signaling.
Campbell PM; Groehler AL; Lee KM; Ouellette MM; Khazak V; Der CJ
Cancer Res; 2007 Mar; 67(5):2098-106. PubMed ID: 17332339
[TBL] [Abstract][Full Text] [Related]
35. Synergistic activation of c-fos promoter activity by Raf and Ral GDP dissociation stimulator.
Okazaki M; Kishida S; Hinoi T; Hasegawa T; Tamada M; Kataoka T; Kikuchi A
Oncogene; 1997 Feb; 14(5):515-21. PubMed ID: 9053849
[TBL] [Abstract][Full Text] [Related]
36. K-Ras4B phosphorylation at Ser181 is inhibited by calmodulin and modulates K-Ras activity and function.
Alvarez-Moya B; López-Alcalá C; Drosten M; Bachs O; Agell N
Oncogene; 2010 Nov; 29(44):5911-22. PubMed ID: 20802526
[TBL] [Abstract][Full Text] [Related]
37. Opposite role of Ras in tumor necrosis factor-alpha-induced cell cycle regulation: competition for Raf kinase.
Park SJ; Kim YY; Lim JY; Seo GJ; Kim J; Park SI; Park BJ
Biochem Biophys Res Commun; 2001 Oct; 287(5):1140-7. PubMed ID: 11587542
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic Ras blocks anoikis by activation of a novel effector pathway independent of phosphatidylinositol 3-kinase.
McFall A; Ulkü A; Lambert QT; Kusa A; Rogers-Graham K; Der CJ
Mol Cell Biol; 2001 Aug; 21(16):5488-99. PubMed ID: 11463831
[TBL] [Abstract][Full Text] [Related]
39. Distinct requirements for Ras oncogenesis in human versus mouse cells.
Hamad NM; Elconin JH; Karnoub AE; Bai W; Rich JN; Abraham RT; Der CJ; Counter CM
Genes Dev; 2002 Aug; 16(16):2045-57. PubMed ID: 12183360
[TBL] [Abstract][Full Text] [Related]
40. DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters.
Sutton MN; Lu Z; Li YC; Zhou Y; Huang T; Reger AS; Hurwitz AM; Palzkill T; Logsdon C; Liang X; Gray JW; Nan X; Hancock J; Wahl GM; Bast RC
Cell Rep; 2019 Dec; 29(11):3448-3459.e6. PubMed ID: 31825828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
